Clinical trials: System Sclerosis
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Interstitial Lung Disease, Scleroderma
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension.
- Conditions
- Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
- Trial name
- CRUSADE (NCT03726398)
- Testing
- Opsumit 10 Mg Tablet
- Where
- United States
- Sponsor
- Franz Rischard, DO
Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
The purpose is to see how multiple sclerosis (MS) is associated with strength and sensation using MRI, in persons with MS. The investigators will also see whether exercise can improve these symptoms for persons with MS.
- Trial name
- NCT01632293
- Testing
- progressive resistance training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
Epilepsy, Drug Resistant
Piriform Cortex Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Piriform cortex as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy…
- Trial name
- NCT07128563
- Testing
- piriform cortex-DBS
- Volunteers
- 5 people
- Sponsor
- Xuanwu Hospital, Beijing
Systemic Sclerosis, Gastroesophageal Reflux
Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
Proton pump inhibitor (PPI) twice daily dosing regimen-a standard dose therapy for gastroesophageal reflux disease (GERD)-is an effective therapy for uncomplicated GERD in systemic sclerosis (SSc) but there is no data of response…
- Conditions
- Systemic Sclerosis, Gastroesophageal Reflux, Proton Pubm Inhibitor
- Trial name
- NCT03561233
- Testing
- Omeprazole 20mg
- Volunteers
- 250 people
- Sponsor
- Khon Kaen University
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Scleroderma, Interstitial Lung Disease
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection.
- Trial name
- SLSII (NCT00883129)
- Testing
- Mycophenolate mofetil, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 142 people
- Sponsor
- Michael Roth
Systemic Sclerosis (SSc)
DERMATOMICS: Identifying Regulators of Skin Homeostasis
Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life.
- Trial name
- DERMATOMICS (NCT06894654)
- Testing
- Skin punch biopsy, blood sampling, Questionnaire
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Relation Therapeutics
Multiple Sclerosis
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.
- Trial name
- NCT05298670
- Testing
- MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- German University in Cairo
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Scleroderma
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being.
- Trial name
- NCT06880627
- Testing
- Brain Boost group, Waitlist group
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Michigan
Multiple Sclerosis
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting
The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting.
- Trial name
- NCT06261541
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- ABLE Human Motion S.L.
Multiple Sclerosis
Cognitive and Emotion Regulation Training in MS
The investigators propose to conduct a randomized feasibility study of mindfulness meditation training (MMT) relative to an active cognitive training control group and waitlist control group in improving emotional regulation in…
- Trial name
- CERT-MS (NCT02717429)
- Testing
- Mindfulness Meditation, Computerized Cognitive Training
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University
Amyotrophic Lateral Sclerosis
A Study of Ranolazine in ALS
The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
- Trial name
- NCT06527222
- Testing
- Ranolazine
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Swathy Chandrashekhar, MBBS
Healthy, Neurodegenerative Disease
Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in brain research.
- Trial name
- BHR (NCT02402426)
- Where
- United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Amyotrophic Lateral Sclerosis
Multimodal Brain Imaging Study
To explain the key brain network nodes and their brain mechanisms of ALS language cognitive impairment and decline, reveal the neural mechanism of the association between ALS language cognitive impairment and motor executive…
- Trial name
- NCT04960540
- Testing
- MRI,
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Multiple Sclerosis, Kinesiophobia
Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis
The aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.
- Trial name
- NCT06167447
- Testing
- questionnaire and examination
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gazi University
Multiple Sclerosis
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer…
- Trial name
- NCT00331747
- Testing
- Glatiramer acetate
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.